Edgen Stock·Sep 12 2025, 04:00返回
返回
Avidity Biosciences 推进 Del-Zota 加速 FDA 批准用于杜氏肌营养不良症
Edgen Stock·Sep 12 2025, 04:00
[1] Avidity Biosciences：《强力买入》基于Del-Zota (RNA) 加速审批申请 (https://seekingalpha.com/article/4822205-avid ...)[2] Avidity Biosciences: 基于Del-Zota加速审批申请维持“强力买入”评级 - Seeking Alpha (https://seekingalpha.com/article/4636000-avid ...)[3] KalVista Pharmaceuticals 提供运营更新并报告财季财务业绩 (https://vertexaisearch.cloud.google.com/groun ...)